EP0674528A4 - Arzneistoffabgabesystem auf der basis von cyclodextrin und einem polymer. - Google Patents

Arzneistoffabgabesystem auf der basis von cyclodextrin und einem polymer.

Info

Publication number
EP0674528A4
EP0674528A4 EP94902482A EP94902482A EP0674528A4 EP 0674528 A4 EP0674528 A4 EP 0674528A4 EP 94902482 A EP94902482 A EP 94902482A EP 94902482 A EP94902482 A EP 94902482A EP 0674528 A4 EP0674528 A4 EP 0674528A4
Authority
EP
European Patent Office
Prior art keywords
cyclodextrin
delivery system
drug delivery
polymer based
based drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94902482A
Other languages
English (en)
French (fr)
Other versions
EP0674528A1 (de
Inventor
Sheng-Wan Tsao
Lyle M Bowman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Inc
Original Assignee
Insite Vision Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/984,445 external-priority patent/US5332582A/en
Application filed by Insite Vision Inc filed Critical Insite Vision Inc
Publication of EP0674528A1 publication Critical patent/EP0674528A1/de
Publication of EP0674528A4 publication Critical patent/EP0674528A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP94902482A 1992-12-02 1993-12-01 Arzneistoffabgabesystem auf der basis von cyclodextrin und einem polymer. Withdrawn EP0674528A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US07/984,445 US5332582A (en) 1990-06-12 1992-12-02 Stabilization of aminosteroids for topical ophthalmic and other applications
US984445 1992-12-02
US15516793A 1993-11-19 1993-11-19
US155167 1993-11-19
PCT/US1993/011651 WO1994012217A1 (en) 1992-12-02 1993-12-01 Cyclodextrin and polymer based drug delivery system

Publications (2)

Publication Number Publication Date
EP0674528A1 EP0674528A1 (de) 1995-10-04
EP0674528A4 true EP0674528A4 (de) 1996-06-26

Family

ID=26852057

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94902482A Withdrawn EP0674528A4 (de) 1992-12-02 1993-12-01 Arzneistoffabgabesystem auf der basis von cyclodextrin und einem polymer.

Country Status (6)

Country Link
EP (1) EP0674528A4 (de)
JP (1) JPH08503951A (de)
CN (1) CN1103316A (de)
AU (1) AU672862B2 (de)
CA (1) CA2150554A1 (de)
WO (1) WO1994012217A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW434023B (en) * 1995-09-18 2001-05-16 Novartis Ag Preserved ophthalmic composition
JP3940209B2 (ja) * 1996-11-14 2007-07-04 株式会社資生堂 可溶化化粧料
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6656456B2 (en) * 1998-11-23 2003-12-02 The Procter & Gamble Company Skin deodorizing compositions
CN1328443A (zh) * 1998-11-23 2001-12-26 宝洁公司 皮肤除臭和卫生消毒组合物
EP1938799B1 (de) * 2000-03-10 2013-05-08 Insite Vision Incorporated Mittel zur Behandlung und Vorbeugung von Erkrankungen der hinteren Augenkammer und deren Verwendung
JP4870314B2 (ja) 2000-05-02 2012-02-08 セラヴァンス， インコーポレーテッド シクロデキストリンを含むグリコペプチド抗生物質組成物
US6770621B2 (en) 2000-05-02 2004-08-03 Theravance, Inc. Polyacid glycopeptide derivatives
US6828299B2 (en) 2000-06-22 2004-12-07 Theravance, Inc. Polyhydroxy glycopeptide derivatives
UA75083C2 (uk) 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
US6872804B2 (en) 2000-06-22 2005-03-29 Theravance, Inc. Glycopeptide disulfide and thioester derivatives
DE60133198T2 (de) 2000-06-22 2009-03-12 Theravance, Inc., South San Francisco Glykopeptidderivate mit carboxysacchariden
AU2001288120A1 (en) * 2000-09-26 2002-04-08 Kyorin Pharmaceutical Co. Ltd. Liquid prednisolone sodium phosphate preparation
WO2002092106A1 (en) * 2001-05-11 2002-11-21 Pacific Pharmaceuticals Limited Taste masking pharmaceutical composition
CA2527175A1 (en) * 2003-04-18 2004-10-28 Advanced Medicine Research Institute Remedies for diseases to be applied to eye
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
WO2006040839A1 (ja) * 2004-10-15 2006-04-20 Advanced Medicine Research Institute 眼疾患処置用点眼剤及びキット
JP2007177149A (ja) * 2005-12-28 2007-07-12 Shield Lab:Kk チオクト酸又はジヒドロリポ酸と分岐鎖シクロデキストリンとの包接化合物
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
JP5623288B2 (ja) * 2007-12-21 2014-11-12 エイオーピーオーファン ファーマスーティカルズ アクチエンゲゼルシャフトＡＯＰ Ｏｒｐｈａｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 医薬組成物
US10201548B2 (en) 2009-03-06 2019-02-12 Sun Pharma Global Fze Methods for treating ocular inflammatory diseases
US10980818B2 (en) 2009-03-06 2021-04-20 Sun Pharma Global Fze Methods for treating ocular inflammatory diseases
EP2627292B1 (de) 2010-10-15 2018-10-10 Clearside Biomedical, Inc. Vorrichtung für okularen zugang
EP3721872A1 (de) 2012-11-08 2020-10-14 Clearside Biomedical Inc. Verfahren zur behandlung von augenkrankheiten bei menschen
WO2014127018A1 (en) * 2013-02-12 2014-08-21 Ys Pharmtech Epinephrine formulations for medicinal products
KR102282973B1 (ko) 2013-05-03 2021-07-27 클리어사이드 바이오메디컬, 인코포레이드 안구용 주사를 위한 장치 및 방법
US10010447B2 (en) 2013-12-18 2018-07-03 Novartis Ag Systems and methods for subretinal delivery of therapeutic agents
CN103990137A (zh) * 2014-04-30 2014-08-20 福建融和药业有限公司 一种粘膜粘附性聚合物眼用药物的缓释剂
WO2017139375A1 (en) 2016-02-10 2017-08-17 Clearside Biomedical, Inc. Ocular injection kit, packaging, and methods of use
EP3452165A1 (de) 2016-05-02 2019-03-13 Clearside Biomedical, Inc. Systeme und verfahren zur verabreichung eines augenmedikaments
CN110177527B (zh) 2016-08-12 2022-02-01 科尼尔赛德生物医学公司 用于调节药剂递送用针的插入深度的装置和方法
US12090294B2 (en) 2017-05-02 2024-09-17 Georgia Tech Research Corporation Targeted drug delivery methods using a microneedle
CN109136177B (zh) * 2018-08-03 2021-09-17 湖南大学 一种地塞米松缓释体系以及一种成骨分化诱导液和应用
RU2740287C1 (ru) * 2019-08-30 2021-01-12 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) 3д-матриксная структура для доставки лекарственных препаратов
CN115380899A (zh) * 2022-08-30 2022-11-25 陕西科技大学 一种凝胶型腐植酸缓释农药及其制备方法
WO2024097388A1 (en) * 2022-11-03 2024-05-10 Arizona Board Of Regents On Behalf Of The University Of Arizona Systems and methods for monitoring fatty acid metabolism

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0300526A2 (de) * 1987-07-01 1989-01-25 Janssen Pharmaceutica N.V. Cyclodextrine enthaltende antivirale Arzneimittel
EP0399716A1 (de) * 1989-05-24 1990-11-28 Innovet, Inc. Hypoallergene anästhesierende/hypnotische steroide Arzneizubereitung
EP0463653A1 (de) * 1990-06-07 1992-01-02 PHARMACIA S.p.A. Zyklodextrine enthaltende galenische Zusammensetzungen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
IE63392B1 (en) * 1988-02-08 1995-04-19 Insite Vision Inc Ophthalmic suspensions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0300526A2 (de) * 1987-07-01 1989-01-25 Janssen Pharmaceutica N.V. Cyclodextrine enthaltende antivirale Arzneimittel
EP0399716A1 (de) * 1989-05-24 1990-11-28 Innovet, Inc. Hypoallergene anästhesierende/hypnotische steroide Arzneizubereitung
EP0463653A1 (de) * 1990-06-07 1992-01-02 PHARMACIA S.p.A. Zyklodextrine enthaltende galenische Zusammensetzungen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9412217A1 *

Also Published As

Publication number Publication date
AU672862B2 (en) 1996-10-17
JPH08503951A (ja) 1996-04-30
WO1994012217A1 (en) 1994-06-09
EP0674528A1 (de) 1995-10-04
CA2150554A1 (en) 1994-06-09
AU5684194A (en) 1994-06-22
CN1103316A (zh) 1995-06-07

Similar Documents

Publication Publication Date Title
EP0674528A4 (de) Arzneistoffabgabesystem auf der basis von cyclodextrin und einem polymer.
EP0662851A4 (de) ABGABESYSTEM FüR MEDIKAMENTE.
AU664807B2 (en) Drug delivery system
AU3127697A (en) Intravenous catheter and delivery system
IL117706A (en) Powdered drug storage and delivery system
AU4989993A (en) Drug delivery system
ZA988203B (en) Aerosol medication delivery apparatus and system.
AU3204995A (en) Closed drug delivery system
AU9617698A (en) Polymeric systems for drug delivery and uses thereof
EP0647133A4 (de) Zusammensetzungen und verfahren zur verbesserte arzneimittelabgabe.
ZA967502B (en) Medicament delivery device.
AU7676894A (en) Convection-enhanced drug delivery
AU3290397A (en) Gastric-retentive oral controlled drug delivery system with enhanced retention properties
ZA918526B (en) Drug delivery system and method
AU4406793A (en) Water-soluble polymeric carriers for drug delivery
EP0671165A3 (de) Injizierbares Verabreichungssystem für Arzneistoffe auf Kollagen-Basis und seine Verwendung.
AU1719800A (en) Drug delivery systems and methods
EP0648239A4 (de) Biovertragliches polymerkonjugat.
EP0702966A3 (de) Kontrastmittelabgabesysteme mit patientenspezifischer Dosierung sowie entsprechendes Verfahren
AU4468197A (en) Hyaluronic drug delivery system
AU660290B2 (en) Multiple drug delivery system
GB9325330D0 (en) Fluorocyclodextrin drug delivery system
AU1671997A (en) Drug delivery system using galactoxyloglucan
EP0636363A3 (de) Verabreichungssystem für Arzneistoffe.
GB9404293D0 (en) Drug delivery system

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950529

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19960509

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19980202

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19980813